TS 033

Drug Profile

TS 033

Alternative Names: SGL 0010; TS-033

Latest Information Update: 09 Oct 2008

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Sodium-glucose transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus (PO)
  • 02 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO)
  • 02 Oct 2008 Discontinued - Phase-II for Type-1 diabetes mellitus (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top